candesartan has been researched along with Liver Steatosis in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Georgescu, EF | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Carlberg, B | 1 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 1 |
| Lind, L | 1 |
1 review available for candesartan and Liver Steatosis
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
1 trial available for candesartan and Liver Steatosis
| Article | Year |
|---|---|
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |